180 Epizód

  1. Adjuvant Therapy for Stage II Colon Cancer Guideline Update

    Közzétéve: 2021. 12. 22.

  2. Management of Stage III NSCLC Guideline

    Közzétéve: 2021. 12. 22.

  3. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

    Közzétéve: 2021. 12. 21.

  4. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline

    Közzétéve: 2021. 12. 13.

  5. Abemaciclib with Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

    Közzétéve: 2021. 12. 10.

  6. Considerations for the Use of Steroids: Management of irAEs Guideline (Part 13)

    Közzétéve: 2021. 11. 16.

  7. Ocular Toxicities: Management of irAEs Guideline (Part 12)

    Közzétéve: 2021. 11. 15.

  8. Cardiovascular Toxicities: Management of irAEs Guideline (Part 11)

    Közzétéve: 2021. 11. 12.

  9. Hematologic Toxicities: Management of irAEs Guideline (Part 10)

    Közzétéve: 2021. 11. 11.

  10. Nervous System Toxicities: Management of irAEs Guideline (Part 9)

    Közzétéve: 2021. 11. 10.

  11. Renal Toxicities: Management of irAEs Guideline (Part 8)

    Közzétéve: 2021. 11. 09.

  12. Musculoskeletal Toxicities: Management of irAEs Guideline (Part 7)

    Közzétéve: 2021. 11. 08.

  13. Endocrine Toxicities: Management of irAEs Guideline (Part 6)

    Közzétéve: 2021. 11. 05.

  14. Lung Toxicities: Management of irAEs Guideline (Part 5)

    Közzétéve: 2021. 11. 04.

  15. Gastrointestinal Toxicities: Management of irAEs Guideline (Part 4)

    Közzétéve: 2021. 11. 03.

  16. Cutaneous Toxicities: Management of irAEs Guideline (Part 3)

    Közzétéve: 2021. 11. 02.

  17. ICPi Overview: Management of irAEs Guideline (Part 1)

    Közzétéve: 2021. 11. 01.

  18. CAR-T Cell Therapy: Management of irAEs Guideline (Part 2)

    Közzétéve: 2021. 11. 01.

  19. Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendation Update

    Közzétéve: 2021. 08. 18.

  20. Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

    Közzétéve: 2021. 08. 03.

5 / 9

Explore pivotal recommendations from the latest evidence-based clinical practice guidance with ASCO Guidelines. Join us to discover essential insights and navigate the ever-evolving landscape of cancer research and treatment.

Visit the podcast's native language site